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required a small increase in core temperature to 33.6*0.15”C. Meperidine and buspirone 
did not cause respiratory depression or other complications. Patients with shivering were 
younger (54 * 10 years vs. 59 * 12 years. p=O.O4), and received a higher total bolus 
dose of meperidine than those without shivering (156 f 66mg vs. 120 f 66mg, p=O.Ol). 
Mean patient weight and body surface area were similar in bath groups and no other 
demographic, clinical or hemodynamlc predictors of shivering were identified. 
Conclusion: Our results indicate that combination treatment with surface warming, bus- 
pirone and meperidine is safe and effective in patients with AMI, and provides a novel 
method for counteracting thermoregulatory defenses to systemic hypothermia during 
endovascular cooling. 
SES to control bare stents (CS), 462 pts (44%) had single vessel LAD treatment. In this 
cohort, reference vessel size was 2.74mm and lesion length was 14.0 mm. 
Results: Clinical (@ 9 months) and angiographic (@ 8 months) outcomes were com- 
pared in the SES and CS LAD subgroups (see table). 
Conclusions: The SIRIUS LAD substudy indicates striking improvement after SES in all 
clinical and angiographic efficacy parameters compared with CS. These SES results are 
equivalent to those reported after LIMA surgery, and thus, SES should be considered the 
new standard of care for stngle vessel LAD therapy. 
Follow-up parameter 
TLR (“‘o) 
TVR (%) 
MACE (%) 
Res (%): in-stent 
Res (%). In-lesion 
SES (n=234) CS (n=228) p value 
5.4 21.2 <O.OOl 
7.6 23.0 <O.OOl 
8.8 22.9 <O.OOl 
2.0 41.6 <O.OOl 
10.1 41.6 <O.OOl 
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1198-178 Volumetric Analysis of In-Stem lntimal Hyperplasia in 
Diabetic Patients Treated With or Without Abciximab: 
Results of the DANTE Randomized Trial 
Aurea J. Chaves, Luiz Mattes, Alexandre A. Abizaid, Rodolfo Staico. Fausto Feres, 
Marinella Centernero, LUIZ F. Tanajura, Andrea S. Abizaid, Ana S&as. lbraim Pinto, 
Marco Costa, Arilson Radrigues, Angela Paes, Amanda Sousa, Jose Eduardo M. Sousa, 
lnstituto Dante Pazzanese de Cardiologia. Sao Paula, Brazil 
Background: EPISTENT data showed that diabetic patients treated with stentiabcix- 
imab had their target vessel revascularlzation (TVR) reduced by approximately 50% 
when compared to stenffplacebo. Whether this is a result of a lower angiographic rest- 
enosis rate remains a subject of debate. Objective: To determine if abciximab is associ- 
ated with a reduced in-stent neointimal hyperplasia (IH), measured by intravascular 
ultrasound (IVUS), in diabetic patients. Method: The DANTE trial enrolled 96 diabetic 
patients (96 lesions) who underwent elective MULTILINK stat implantation for a de nova 
lesion of a native coronary artery randomized to be treated with or without abciximab. 
They were scheduled to undergo a 6.month angiographic and IVUS evaluation. Sample 
size calculations showed that 44 stented lesions/arm would be required to show a 25% 
reduction I” IH. Results: 
StenffAbciximab (n=47) Stem (n=49) p 
Age. Y 
Female, % 
Insulin Treated, % 
56.9 f 9.8 
46.8 
19.1 
Lesion Length, mm 11.5 * 4.7 
Stented Segment, mm 18.1 e4.0 
Reference Diameter, mm 2.99 * 0.49 
MLD pre 0.95 * 0.46 
MLD post 2.77 * 0.39 
MLD fup 1.75 * 0.69 
Acute Gain, mm 1.81 * 0.42 
Late LOSS, mm 1.03 * 0.63 
250% Restenosis, % 17.8 
30.day MACE, % 0 
60.6 f 8.5 
55.1 
16.3 
11.0 * 3.5 
19.8 f 5.6 
2.89 * 0.47 
0.84 * 0.35 
2.72 f 0.42 
1.66 f 0.63 
1.88 * 0.47 
1.07 * 0.58 
22.9 
0 
0.375 
0.416 
0.717 
0.537 
0.106 
0.283 
0.187 
0.574 
0.388 
0.484 
0.736 
0.539 
6month MACE, % 10.6 
NR, % 8.5 
Neointimal Volume, mm3 53.6 * 28.5 
Volume Obstruction, % 41.3 * 21.0 
MACE: death, Ml @-3x CKMB) or TVR 
22.4 0.121 
16.3 0.274 
60.7 + 40.8 0.344 
40.5 * 18.3 0.853 
Conclusion: In our study, volumetric analysis obtained in the d-month IVUS evaluation, 
showed that the administration of abciximab at the time of coronary stent implantation, 
was not associated with a reduction of neointimal hyperplasia in diabetic patients. 
1198-l 79 Should Sirolimus-Eluting Stents Be the New Standard 
for Left Anterior Descending Therapy? A SIRIUS 
Substudy 
Jeffrev W. Moses Dean Kereiakes, David 0. Williams, John Douglas, Charles Lambert. 
Charles Simonton, Michael Cleman, Charles Davidson, Timothy Vellinga, Martin B. 
Leon, Cardiovascular Research Foundation, New York, NY 
Background: The universal adoption of stenting to treat single vessel LAD disease has 
been llmited by increased target vessel revascularization -20.30%. leading to the pro- 
posal of LIMA surgery as an alternative therapy. Importantly, the effects of sirolimus-elut- 
Ing stents (SES) on LAD restenosis (Res) is not well defined. 
Methods: Of the 1058 pts in the randomized double-blind SIRIUS trial, which compared 
TLR=target lesion revascularizatlon 
TVR=target vessel revascularization 
MACE = major adverse cardiac events (death, MI, and repeat revascularlzation) 
1198-180 Effects of Sirolimus-Eluting Stents in Diabetic Patients: 
Volumetric Intravascular Ultrasound Analysis From the 
SIRIUS Trial 
Junva Ako, Yoshihiro Morino, Yasuhiro Honda, Shinjo Sonoda, Mitsuyasu Terashima, Ali 
Hassan, Judith J. Jaeger, Charles A. Simonton, David K. Roberts, Michael W. Cleman, 
Martin B. Leon, Jeffrey W. Moses, Paul G. Yock, Peter J. Fitzgerald. the SIRIUS 
investigators, Stanford University, Stanford, CA, Lenox Hill Hospital, New York NY 
Background: Exaggerated intimal hyperplasia has been reported to contribute to 
increased restenosis after percutaneous coronary tnterventlons in diabetic patients. The 
effects of drug-eluting stents in diabetic patients have not been well investigated. 
Methods: IVUS data were obtained from SIRIUS, a prospective, randomized, multi- 
center trial comparing sirolimus-eluting Bx VELOCITY stents (SES) vs. bare metal Bx 
VELOCITY stems (BMS). Eight-month follow-up 3-D IVUS analysis was available in 95 
cases (BMS 44: SES 51). Mean lumen (LA), stent @A), and neointimal areas (NIA) were 
obtained by dividing each volume with stent length. Cross sectional narrowing (CSN) 
was calculated as NIA divided by SA. The variables were compared by stent types (SESI 
EMS), presence of diabetes, and their Interactions. 
Results: There were 25 diabetic patients (BMS 13: SES 12). BMS showed a trend of 
decreased LA in diabetic patients compared to non-diabetic patients (p=O.O8). SES sig- 
nificantly suppressed neointimal hyperplasia in both diabetic and non-diabetic patients. 
There was no significant interaction effect between stent types and diabetes, indicating 
that the extent of neointimal suppression by SES was not affected by the presence of 
diabetes. 
Conclusions: Volumetric IVUS results of the SIRIUS trial suggest that sirolimus-eluting 
stents can provide suppression of neointimal hyperplasia that is as substantital in dia- 
betic patients as in non-diabetic patients. 
Table (*p=O.O8 vs. DM(-). BMS) 
BMS (n=44) SES (n=51) p-value 
NIA (mm3lmm) DM(-) 2.5il.3 0.18iO.3 <0.0001 
DM(+) 2.4kl.2 0.01*0.13 
LA (mm3lmm) DM(-) 5.3kl.7 6.7e2.0 <0.001 
DM(+) 4.3il.7’ 6.221.8 
%CSN DM(-) 31.4k12.8 2.8+5.1 <0.0001 
DM(+) 36.1i16.8 1.7i2.1 
Minimum lumen area (mm2) DM(-) 3.2kl.3 5.ikl.8 <0.0001 
DM(+) 3.1+2.0 4.5*1.7 
1198-181 About the Use of the ACHIEVE Paclitaxel Eluting 
Stent in Treatment of Restenotic Lesions: A 
Subanalysis of the 30-Day Safety Data of DELIVER II 
Antonio L. Bartorelli, Eberhard Grube, Didier Blanchad. Anthony Genhlick. Carlos 
Macava. Sophie Henrv. ChrIstran Homsv. on behalf of the DELIVER II investiaators. 
Centro Cardiologico Monzino, Milano, Italy, GUIDANT Europe, Diegem, Belgium 
Background: Many interventional cardiologists believe that restenosls following angio- 
plasty or stating is the most significant and pressing problem in the field of cardiology 
today. Stenting of coronary arteries resulted in a reduction of restenosis to 15.30% fol- 
lowing treatment of de nova lessons. But when restenosis of a stent does occur, recur- 
rence of in-stent restenosis treated with repeat PTCA ranges from 30% to as high as 
80% for diffuse in-stent restenosis. The DELIVER II study is a 1500 patients prospective, 
non-randomized, multi-center evaluation of the ACHIEVETM paclitaxel eluting Coronary 
Stat System in the treatment of lesions with high risk of revascularization due to rest- 
enosis. Such lesions include Chronic Total and Sub-Total Occlusions &TO). lesions 
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involving a bifurcation site, restenotic lesions (including in-stent restenosis). two-vessel 
disease (a maximum of 2 lesions located in 2 different epicardial vessels), long lesions 
(up to 53 mm). 
Methods: The primary endpoint of the study is the Target Lesion Revascularization 
(TLR) rate at 160 days after stent implantation. Secondary endpoints are Target Vessel 
Failure (TVF) at 160-days, Major Cardiac Events (MACE) at 30-days and 160-days, 
MACE at l-year, P-years and 3-years in a subset of 500 patients, device succsss, procs- 
dure success and resource utilization. 
Results: As of abstract submission, data about 1252 patients enrolled at 60 investiga- 
tional sites is available for analysis, for a total of 1435 lesions treated. Among these, 374 
(34%) ware restenotic lesions. 
Conclusions: The patient recruitment in the DELIVER II study was completed on gt” of 
September 2002. Thirty-day safety results from the restenotic lesions subgroup will be 
available for presentation .and will be compared with the outcome of other lesion sub- 
groups. Multivariate analysis combining restenosis with other complicating factors will be 
presented as well. 
* Manufactured by Cook Incorporated. DELIVER II is conducted by Guidant Corporation 
on behalf of Cook Incorporated. 
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Cosico, Alexandra J. Lansky, Jeffrey W. Moses, Gregg W. Stone, Martin B. Leon. 
George Dangas, Lenox Hill Heart and Vascular Institute, Cardiovascular Research 
Foundation, New York, NY, Columbia University, New York, NY 
Background: Rapamycin, a maciolide antibiotic, inhibits SMC proliferation in vitro and in 
viva by blocking cell cycle progression at the GlIS transition. Given the anti-proliferative 
and anti-migratory properties of rapamycin, it may have anti-restenosis properties after 
PTCA and placement of coronary stsnts. Recently, implantation of rapamycin (sirolimus) 
eluting stems in de now lesions was shown to be safe and effective in inhibiting neointi- 
mal formation. The safety and efficacy of oral rapamycin in reducing the incidence of inti- 
mal hyperplasia and restsnosis is not known. 
Methods: Thirty Patients with stable exertional angina will receive standard therapy 
(ASA + Clopidegrol) plus rapamycin (loading dose 6 mg on the day of the procedure, fol- 
lowed by 2 mg/day) for either 2 (phase 1, n=15) or 4 (phase II, n=15) weeks after stent 
implantation for denovo lesions. Blood will be obtained for rapamycin levels, CBC, renal 
function and lipid profile. Quantitative coronary angiography @CA) and IVUS imaging 
will be performed immediately after the procedure and at a 6 month follow-up in all 
patients for evaluation of the primary endpoint of neointimal volume and binary resteno- 
sis. Results: To date, 15 (completed study-phase one) patients (mean age 60*10. 70% 
males, 27% diabetics, 40% prior MI) have been enrolled. All patients tolerated the load- 
ing dose plus two week course of oral Rapamycin without any significant side effects or 
laboratory abnormalities. There was one episode of recurrent in-hospital ischemia (few 
hours after the procedure) for suboptimal angiographic result which required further 
stenting. Angiographic and IVUS follow-up is in progress and will be presented for these 
patients as well as the full safety data on all 30 patients. 
1198-183 Oral Rapamune to Inhibit Restenosis in Patients With 
Multi De-Novo Coronary Lesions Requiring Stenting 
Ron Waksman, Andrew E. Ajani, August0 D. Pichard. Ellen Pinnow, Lowell F. Satler. 
Kenneth M. Kent, Neil J. Weissman, Rebecca Torguson, Louise Gambone, Maureen 
Abbott, Peter Iloanya, Joseph Lindsay, Washington Hospital Canter, Washington, DC 
Background: Drug-eluting stents (utilizing antiproliferative agents such as Rapamune) 
have shown the ability to limit restenosis. Oral Rapamune (R) is an alternative delivery 
strategy that can target multi-stenosed coronary vessels and may potentially lower the 
cost and vessel toxicity. 
Methods: The Cal Rapamune to Inhibit Restenosis (ORBIT) is an open label study of 
60 patients (pts) with de nova coronary artety stewsis treated with stent implantation in 
up to 2 vessels. The first 30 pts received R 2 mg /day for 30 days, and the last 30 pts 
received R 5mgIday for 30 days. The loading dose for both regimens was 5 mg given 
either immediately prior to or after the intervention. Patients underwent clinical and 
angiographic follow-up. 
Results: In the first 30 patients who received R 2 mg/day (age 60 * 10 years, 66% 
males, 13.3% diabetes), the mean number of treated lesions par pt was 1.6 f 0.5, with a 
reference vessel diameter of 3.0 r 0.5 mm and mean lesion length of 19.7 * 9.0 mm. 
Angiographic success was achieved in all pts. Mean pre-discharge serum R levels were 
5.1 f 3.1 ng/ml and at 30 days 6.5 + 4.2 (17 pts). Drug therapy was discontinued in 3 pts 
from the 2 mg group and in 5 pts from the 5 mg group due to skin rash, diarrhea, mouth 
ulcers, or fatigue (or a combination of these symptoms). There were no biological or bio- 
chemical adverse affects. 
In the 2 mg group, 49 lesions were treated. Of these, 40 were available for angiographic 
follow-up. The binary restenosis for in-stent was 5.0% and for in-segment was 7.5%. The 
late loss in-stent was 0.62 f 0.61 and the in-segment was 0.29 f 0.52 mm. Target lesion 
and vessel revascularization was 15.6%. Conclusions: Oral Rapamune administration 
for the prevention of restenosis is safe and feasible. Low rates of restenosis and late loss 
were observed with a dose of 2 mgiday. Complete g-month follow-up for the R 5mgld 
group will be available at presentation. 
1198-164 Stent Release of a Rapamycin Analogue: Tissue 
Pharmacoklnetics of Rapid Versus Delayed Release 
Frederick G. Walt, Elazer R. Edelman, Neda Vukmirovic, Campbell Rogers, Harvard- 
MIT, Cambridge, MA, Brigham and Woman’s Hospital, Boston, MA 
Bsckground:The effect of drug release rates from stents on tissue uptake and biologic 
effect are poorly understood. We investigated tissue distribution under varied release 
conditions of a stent-delivered rapamycin analogue. Methods and Resultsd6 rabbits 
underwent iliac artery stenting with a stent coated with a phospholylcholine polymer 
loaded with 3H drug (100 ).&tent). We compared 2 formulations: formulation l- rapid 
release, and formulation 2- slow release. Animals were harvested at 1. 3. 7, 14, and 28 
days and stent and tissue drug concentration determined through liquid scintillation 
counting. In viva drug release from formulation 1 was >90% at 3 days. Release from for- 
mulation 2 did not reach >90% until 14 days(P=0.005 by ANOVA). Arterial deposition 
peaked at 1 day with formulation 1 (726.0+154.3 pg/g tissue) and at 3 days in formulation 
2 (1339.0*412.6 pglg tissue). When plotted against percent of drug released from stew. 
efficiency of deposition (pg drug/g tissue/pg drug released) from formulation 2 was best 
fit by a polynomial equation (R* 0.64, p<O.OOl) and was greater (p=O.O4 by ANOVA) than 
efficiency from formulation 1 which was best fit by a linear equation (R2 0.56, 
p<O.OOl)(Figure). Conclusion: Delayed release enhances the efficiency of delivery of a 
rapamycin analogue to tha vessel wall. Modulating release may offer a more effective 
method of enhancing stent-based drug delivery than increasing dose. 
1198-l 85 Can Sirolimus-Elutlng Stents Tolerate Some Degree of 
Geographic Miss? 
Cherukupalli Raahu, Yves Louvard, Marie-Claude Morice, Carlo di Mario, Martin Leon, 
Jeffrey Moses, Judith Jaeger, Josef Ludwig, David Holmes, Antonio Colombo, lnstitut 
Cardiovasculaire Paris Sud, Massy, France, Centro Cuore Columbus, Milan, Italy 
Background. Sirolimus-eluting stems have proven their ability to almost completely sup- 
press 6.month neointimal proliferation in the stented segment. However, linls is known 
on the efficacy in the segments adjacent to the stent, dilated but not stented. 
Methods and Results. In a multicenter randomised bifurcation trial, between June 2001 
and April 2002, 66 pts with a significant stenosis at a bifurcation ware enrolled. The effi- 
cacy of sirolimus-eluting stents in these lesions has been evaluated. Pts were ran- 
domised into 2 groups of 43 each to receive either 2 stents (main vessel and branch) or 1 
stent (main vessel only). At the operator’s discretion 22 patients in the single stent arm 
have crossed over to the 2 stent arm. Baseline characteristics were comparable in both 
groups: mean age 63etO years, males 60.2%, diabetes 22%, and unstable angina 
17.4%. 
By means of QCA, films of 47 pts were analyzed before and after Intervention and at 6- 
months for the presence of geographic miss and its effect on restenosis. 5 patients who 
had acute procedural failure ware excluded from the analysis. Geographic miss has been 
defined as any balloon inflation beyond the non-stented segment. The segments proxi- 
mal and distal to the stent in the main vessel as well as the side branch have been exam- 
ined for geographic miss. 
Conclusion. Even in the era of drug-eluting stems, the process of restenosis is multifac- 
torial and the presence of geographic miss does not seem to influence the restanosis 
rates in bifurcation lesions. 
Study Group Restenosis 
No geographic miss (17/42) 6 (35%) 
Geographic miss (25/42) 4 (16%) 
Main vessel (10) 
Proximal to stent(4) 0 
Distal to stent (6) 1 
Side branch(l9) 3 
1198-186 Association Between Progression of Untreated 
Coronary Lesions and In-Stent Restenosis 
Dirk Skowasch, Joachim Vaerst, Alexander Jabs, Rend AndriB, Berndt Liideritz, Gerhard 
Baurisdel University of Bonn, Bonn, Germany -. 
Background: Progression of coronary artery disease is not completely understood, nei- 
ther for de-now stenoses nor for in-stent restenosis (ISR) as accelerated arteriosclero- 
sis. The objective of this angiographic study was to assess an association between 
presence of ISR and the progression of untreated coronary lesions. 
Methods: A Series of 212 high-grade native coronary stenoses (mean stenotic degree 
66%) of 150 patients was treated by stent implantation; 129 additional lesions with mild 
to moderate stenoses (>30%) remained untreated. Quantitative coronary angiography 
analysis was performed after 6+2 months regarding ISR (stenosis >50%), coronary pro- 
gression (increase in stenosis >20%) and regression (decrease >20%), rasp. Angio- 
graphic, procedural and clinical characteristics were assessed for a possible association 
to ISR and/or coronary progression. 
